Full Press Release Details
Sanofi-aventis Announces Court Decision
Eloxatin U.S. Patent Litigation
Eloxatin Expected to Recover in the U.S. Market -
Paris, France April 23, 2010 - Sanofi-aventis (EURONEXT:SAN and NYSE: SNY) announced today that Sun Pharmaceuticals will be
required to cease selling its infringing generic version of Eloxatin (oxaliplatin) on June 30, 2010 by order of the
U.S. District Court for the District of New Jersey. This order clarifies the previously announced Eloxatin settlement
agreements requiring all defendant generic manufacturers to cease sales of their infringing products as of that date and resolves the litigation over certain formulations of oxaliplatin in the U.S. District Court for the District of New
Jersey and the U.S. District Court for the District of Columbia.
This announcement follows a recent set of settlement agreements between sanofi-aventis
and Debiopharm (licensor of the involved patent rights) and certain generic manufacturers, namely Teva Pharmaceuticals USA, Inc., Fresenius Kabi (formerly Dabur), Sandoz, Mayne/Hospira, MN/Par and Actavis, some of which are selling infringing
generic oxaliplatin products. Under the terms of these settlement agreements, the generic manufacturers would cease selling their infringing generic oxaliplatin products in the U.S. from June 30, 2010, to August 9, 2012, at which time the
generic manufacturers would be authorized to sell generic oxaliplatin products under a license, before expiry of the patents at issue. The rest of the settlement provisions are confidential. Moreover, all of the settlement provisions, including the
dates noted above, are subject to contingencies.
The lawsuits relate to the quality and formulation of oxaliplatin, available in
the U.S. under the brand name Eloxatin . The settlement agreements are subject to review by the Federal Trade Commission,
the U.S. Department of Justice and the Attorney General for the State of Michigan.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to help improve the lives of patients.
Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, www.sanofi-aventis.us or www.sanofi-aventis.com
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events,
operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates, believes,
intends, estimates, plans and similar expressions. Although sanofi-aventis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data
and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as
their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives, the Group s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by
sanofi-aventis, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in sanofi-aventis annual report on Form 20-F for the year ended December 31, 2009. Other
than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.